ArticleGastroenterology research and practice2026
Association Between Serum PADI-4 Levels and Disease Activity in Ulcerative Colitis Patients.
Article in Gastroenterology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between Serum PADI-4 Levels and Disease Activity in Ulcerative Colitis Patients.Gastroenterology research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: PADI-4 is a member of the peptidyl arginine deiminase enzyme family. This enzyme is expressed by inflammatory cells and plays an important role in inflammation and immune responses. In this study, we aimed to evaluate serum PADI-4 levels in patients with ulcerative colitis (UC) and to investigate the relationship between PADI-4 and disease activity. Material and Method: Fifty-one patients with UC and 31 healthy controls were included in this observational study. First, serum PADI-4 levels in patients with UC and the control group were compared. Subsequently, serum PADI-4 levels were analyzed in UC patients with active disease and those who are in remission, separately. Finally, the impact of PADI-4 on predicting disease activity was evaluated by performing correlation analyses between serum PADI-4 and C-reactive protein (CRP) in addition to the total Mayo score (TMS) and modified Mayo Endoscopic Subscore (MESS). Results: Serum mean PADI-4 levels were found to be significantly higher in the UC group (1317 ± 818 pg/mL) compared to the control group (873 ± 622 pg/mL) ( Conclusion: Our study revealed that serum PADI-4 levels were higher in patients with UC compared to healthy controls and might be an effective marker to determine disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.